MedTrace Logo

Objective Confirmation of thе Anti-ischemic Effectiveness of Trimetazidine 80mg Once Daily in Patients With Stable Angina Who Had a History of Myocardial Infarction (METHOD)

NCT05210465 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 36

Last updated 2024-04-18

No results posted yet for this study

Summary

METHOD is a prospective observational program that will be conducted in 1centre of the Russian Federation. Prospective follow-up will be for about 6 months. The METHOD study is a 2 visit study with first visit of inclusion and second visit of completion of the study. Patients with stable angina pectoris eligible to the study inclusion criteria will be invited to participate in this observational program. The parameters for analysis will be collected by doctors and entered into CRF. The final analysis will include data from patients who were taking TMZ 80 mg OD during the observational period. The decision to stop the study will be made once 36 patients receiving treatment with trimetazidine 80 mg OD will have been evaluated at V1.

It is expected that 5 cardiologists will participate in the program. The planned number of patients is 36.

Conditions

Interventions

OTHER

speckle tracking mode of the stress ECHO test with dobutamine

speckle tracking mode of the stress ECHO test with dobutamine

Sponsors & Collaborators

  • Servier Russia

    lead INDUSTRY

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-03
Primary Completion
2023-11-01
Completion
2024-04-17

Countries

  • Russia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05210465 on ClinicalTrials.gov